Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — JMP Securities Healthcare Conference 2011
36 slides from Biolase's conference presentation, Sep 27, 2011
Slide 1: BIOLASE Technology, Inc.
Exhibit 99.1 JMP Securities Healthcare Conference September 27-28, 2011, New York BIOLASE Technology, Inc. Federico Pignatelli, CEO NASDAQ: BLTI www.biolase.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “e
Slide 3: BIOLASE is NOT Just Another Medical Equipment Company!
BIOLASE is NOT Just Another Medical Equipment Company! BIOLASE is revolutionizing surgery by breaking the limitations of conventional dentistry and medicine. New management is transforming BIOLASE from a one product, one segment company of the past to a multi-productandmulti-segment platformcompanyt
Slide 4: Traditional Dentistry
Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 4
Slide 5: How has BIOLASE Revolutionized Surgery?
How has BIOLASE Revolutionized Surgery? …through the science of WaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG (2796nm)
Slide 6: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry? Traditional high-speed drillsworkbyFRICTION whichcreatesHEATwhichcausesPAIN. This PAINnecessitates injectionsofANESTHESIA whichresultsinPAINandNUMBLIPS.In addition, the lack of feeling from the numbing injections can lead to THERMAL DAMAGE which can lea
Slide 7: Alternative and Advanced Hi-Tech Dentistry
Alternative and Advanced Hi-Tech Dentistry Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System: The iPlus features an The aiming beam on intuitive, touch-based the NEW WaterLase computer screen, iPlus is green. This similar to a tablet red beam featured in personal computer. th
Slide 8: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 8
Slide 9: WaterLase vs. Drill
WaterLase vs. Drill BIOLASE BIOLASE
Slide 10: Alternative Dentistry is Less Frightening
Alternative Dentistry is Less Frightening Usingthedentaldrilloffersmoreof thesamewhichispain,localanesthetic, swelling,painkillers,micro- fracturesandcrosscontamination. WaterLase technology offersa biologicalsolutionwithnoneofthedownsides of traditional dentistry: NO drill, NO shot, NO pain, and NO
Slide 11: WaterLase’s Amazing Return on Investment
WaterLase’s Amazing Return on Investment Monthly Lease Payment New Monthly Revenue Generated Approx. $1,000 $5,000 $ –15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or WaterLase dentists, for example: • Gingivectomy = $16
Slide 12: Technology Supported by Scientific Data
Technology Supported by Scientific Data Substantial Data: • The effectiveness of dental lasers is proven and well researched. • Clinical data and peer- reviewed specialty journals substantiate the effectiveness of laser treatment in a wide variety of procedures. PAGE 12
Slide 13: Some of the Dental Schools that are Teaching WaterLase Technology around the World
Some of the Dental Schools that are Teaching WaterLase Technology around the World PAGE 13
Slide 14: Warning: Patients Urged to Ask their Dentists About the Risk of Cross Contamination!
Warning:Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Cross contamination is a huge1,2,3,4 threat : • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the ability to live on objects an
Slide 15: WaterLase Laser Technology Eliminates the Risk of Cross Contamination and Contagion
WaterLase Laser Technology Eliminates the Risk of Cross Contamination and Contagion NO Risk of Cross-Contamination: Burs and Endo Files: WaterLase Tips:2.86 WaterLase MD™reduced E.faecalis times more effectively than NaOCl³ • 15% of “sterilized” burs and up to 76% of “sterilized” • Smooth tip surfac
Slide 16: Intellectual Property
Intellectual Property Award winning IP: • Recognized for innovation, leadership, and the development of numerous disruptive technologies, most notably the development of a new surgical system to cut human tissue in a biological and atraumatic way. • Received Astrum Award at MDB Capital’s 2011 Bright
Slide 17: Patent Portfolio
Patent Portfolio CurrentStatus:BIOLASEcurrentlyhas279issuedandpendingpatents,70%of whicharerelatedtoour core Er;Cr:YSGG technology and medical lasers. Issued Pending Total U.S. 84 46 130 International 74 75 149 Total 158 122 279 Filing costs and maintenance arecloselymonitored.Fundingforredundantpat
Slide 18: Current Line of BIOLASE Products
CurrentLineofBIOLASE Products All-tissue dentallasers:Ourall-tissuelasersincludeournewflagshiplaser,therevolutionary WaterLase iPlus, and the WaterLase MD Turbo. Diodesoft-tissue dentallasers:OursofttissuelasersincludetheezLasetotaldiodesolution, whichofferspowerandportability,andtherevolutionary iL
Slide 19: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for Home Use • BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license agreement with The Proctor and Gamble Company (“P&G”). • Research indicates that a laser toothbrush for home-use
Slide 20: Further Opportunities to Expand in Medicine
Further Opportunities to Expand in Medicine With our patented WaterLase and diode technologies, we have created technological platforms that have the ability to extend far outside of dentistry. This expansion into new markets is a fundamental effort within BIOLASE. We expect to greatly expand our ad
Slide 21: Further Opportunities to Expand in Medicine (Continued)
Further Opportunities to Expand in Medicine (Continued) PainManagement: Weanticipate launchinga newdeep-tissue handpieceandupgraded laserfor pain therapy in 2012 which will coincide with a new marketing campaign. Podiatry: WehavefoundthatourDiolase10technology isveryeffectiveinthetreatmentofnailfung
Slide 22: Foundation for a Successful Recovery
Foundation for a Successful Recovery How BIOLASE is positioned for a successful turnaround: • BIOLASE hasa betterorganizational structure, bettercostcontrol,andmoreefficient& effective management than ever before. • Our lowercoststructureand growingdirectsalesforcewillallowustoleverageourearnings co
Slide 23: How BIOLASE is Positioned in the Dental Market
How BIOLASE is Positioned in the Dental Market BIOLASE United States BIOLASE International 5,700 2,700 6,800 2,800 Total: 12,500 Total: 5,500 Grand Total: 18,000 PAGE 23
Slide 24: Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market
Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market… Biolase 80% Source: Biolase Technology Licensing Reports PAGE 24
Slide 25: …and the Overall Dental Laser Market
…and the Overall Dental Laser Market. 2009 US Dental Laser Market: Hard & Soft Tissue Biolase 45% Source: iData Research Inc. PAGE 25
Slide 26: Our Market Opportunity in Dentistry
Our Market Opportunity in Dentistry BIOLASE’s global market opportunity is tremendous! Our current market penetration is approximately 3% in the United States and slightly less than 1% internationally! 1 • 176,000dentistsin theUSandCanada. 2 • Over1.2milliondentistsin134countries. • 18,000 systems i
Slide 27: Substantial Opportunity in Emerging Markets
Substantial Opportunity in Emerging Markets Practicing Dentists 1 Western Europe Eastern Europe 240,000dentists 120,000dentists 1 dentist / 1,800 population 1 dentist / 4,000 population China North America 16,000 dentists 176,000 dentists Middle East 1 dentist / 82,300 population 1 dentist / 1,900 p
Slide 28: Expected Growth of Emerging Markets
Expected Growth of Emerging Markets 1,2 Emerging Markets are expected to be bigger than Developed Markets by 2050. • Forecasts predict that the top 5 economies in 2050 will include China, the United States, India, Japan, and 1 Germany. • Led by China, at >800%, and India, at >600%, the rise in incom
Slide 29: BIOLASE Technology, Inc. Today
BIOLASE Technology, Inc. Today BIOLASE is the Global Leader in Dental Lasers: • Our 57,000 sq. ft. fcorporate HQ in Irvine houses administrative, sales, marketing, customer care, training, manufacturing, and R&D. This facility can accommodate growth to $250 million. • We also have manufacturing capa
Slide 30: Operations
Operations Manufacturing and Research & Development • We are ISO 9001 certified and FDA GMP with clean room operations. We also have manufacturing capabilities in Floss, Germany. • Nearly 100% of our components and subassemblies are manufactured in our facility and/or the U.S. • We have a highly ski
Slide 31: Chart & Financial History
Chart & Financial History 1994-2006 Pignatelli Aug 2010-Present Exclusive distribution partnership with Pignatelli CEO & Chairman of the Board Henry Schein Aug 2006–Aug 2010Board Chairman 20 15 BLTI SHARE 10 PRICE 1998 FDA Clearance WaterLase 5 1.0 0.5 PAGE 31
Slide 32: Market Data (NASDAQ: BLTI)
Market Data (NASDAQ: BLTI) As of September 15, 2011: Share price……………….....………………………...…………...................................................................... $3.53 Shares issued and outstanding…………………………………………………………....….…………… 30,300,000 Public float (shares held by others than the CEO and Board
Slide 33: Financial Highlights
Financial Highlights Turnaround: FortheninemonthperiodendedJune30,2011,BIOLASE generatednon-GAAP netincome of approximately $885,000, as compared to a non-GAAP net loss of approximately $9.3 million for the nine month period ended June 30, 2010. Insider Purchases: During 2011, officers and directors
Slide 34: Recent Developments
Recent Developments Ophthalmology: In September In June 2011, BIOLASE entered into an agreement with Daniel S. Durrie, M.D.,aninternationally recognizedrefractivesurgeon,toserveasBIOLASE’s primaryophthalmic expert resource and partner with management to oversee the development and execution of our c
Slide 35: Recent Developments (continued)
Recent Developments (continued) DirectSalesinGermany: BIOLASE hasregainedtheabilityto selldirectorthroughotherdistributors from Henry Schein Inc. (NASDAQ: HSIC) for all of its international territories and has announced plans to expand BIOLASE Europe, GMBH, to now include a direct sales force, along
Slide 36: BIOLASE Technology, Inc.
JMP Securities Healthcare Conference September 27-28, 2011, New York BIOLASE Technology, Inc. Federico Pignatelli, CEO NASDAQ: BLTI www.biolase.com
Biolase Technology — JMP Securities Healthcare Conference 2011 on 6ix